Compare Medtronic PLC (MDT) vs NICE Ltd (NICE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs NICE Ltd — how do they compare? Medtronic PLC trades at $88.79 (market cap $112.24B), while NICE Ltd trades at $117.41 (market cap $6.81B). The key difference: Medtronic PLC is far larger — about 16.5× NICE Ltd's market cap, and Medtronic PLC pays a 3.28% dividend while NICE Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and NICE Ltd for 15 Days on average.
| MDT | NICE | |
|---|---|---|
Market Cap | $112.24B | $6.81B |
Volume | 105,663,236 | 382,395 |
Sector | Health | Technology |
52-Week High | $105.35 | $137.68 |
52-Week Low | $73.75 | $83.15 |
Typical Hold Time | 63 Days | 15 Days |
Enterprise Value | $131.58B | $6.54B |
Dividend Yield | 3.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $88.48, up 3.47% today, with a bullish analyst consensus and a $97.80 price target. The stock shows strong fundamentals with revenue growth to $33.54B in 2025 and a net income margin of 13.93%. Recent earnings beats and a 49-year dividend growth streak highlight operational strength, though technical indicators signal a near-term bearish trend with key support at $87.
MDT presents a compelling long-term investment with stable profitability and dividend reliability, but faces risks from debt increases and competitive pressures. Upside potential exists if the company maintains earnings momentum and executes on growth initiatives, while volatility may persist due to market sentiment shifts.
NICE trades at $116.83, up 0.35% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $124.20. The company reported strong Q2 2026 earnings, beating EPS estimates with $2.70 actual versus $2.63 expected, and was recently named a leader in the IDC MarketScape for contact center platforms (Business Wire, 2026-10-01). Revenue for 2025 was $2.95 billion with a net income margin of 20.78%.
The outlook is positive, supported by AI-driven growth and a reasonable valuation with a P/E of 17.08. However, risks include margin compression from increased investment and potential market volatility. Analyst sentiment is bullish with 12 buy ratings and no sells, but investors should monitor execution on AI initiatives and competitive pressures in the CX software space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About NICE Ltd
NICE Ltd. is a global leader in both enterprise software and cloud computing, specializing in customer experience and financial crime prevention solutions. The company's platform utilizes advanced analytics, AI, and automation to help organizations enhance customer interactions, ensure compliance, and combat fraud. NICE serves a diverse client base, including contact centers, financial institutions, and government agencies, by optimizing operations and improving service quality.
Read more on NICE →
